Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-452080 in Subjects With Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 10 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BPI-452080 (Primary)
Indications Renal cell carcinoma; Solid tumours
Focus Adverse reactions
Sponsors Betta Pharmaceuticals Co Ltd

Most Recent Events

24 Apr 2023 Status changed from planning to not yet recruiting.
13 Dec 2022 New trial record
05 Nov 2022 According to Betta Pharmaceuticals media release, "Notice of Acceptance" issued by the company the application for clinical trials of BPI-452080 tablets declared by the company It has been accepted by the State Drug Administration.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com